The majority shareholders of Carmel Pharma AB ("Carmel") have entered into an agreement with BD (Becton, Dickinson and Company) to sell approximately 95% of the ordinary share capital for an undisclosed amount paid in cash. BD has informed Carmel that it intends to make an offer to acquire all remaining outstanding shares in Carmel at the same price offered to the majority shareholders.
Carmel is a worldwide leader in closed drug transfer systems for handling medications. Carmel’s proprietary PhaSeal system, considered to be the gold standard in safe handling, is a unique safety solution designed to protect health care workers, patients, the drug and the hospital’s P&L.
PhaSeal’s double-membrane technology and a unique pressure-equalizing function ensures an air tight, leak proof solution throughout the entire preparation, administration and waste disposal chain.
BD is a leading global medical technology company listed on the New York Stock Exchange (NYSE:BDX) with a market...